Report
Jonathan Moreland
EUR 9.28 For Business Accounts Only

InsiderInsights Daily Ratings Report: April 5, 2023

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process
Underlyings
Appian

Appian provides low-code automation platform that accelerates the creation of business applications, enabling its customers to automate their business. The company's platform automates the creation of forms, data flows, records, reports and other software elements that would otherwise need to be manually coded. The company'snSelf-Assembling Interface Layer technology ensures that applications developed on its platform can be deployed across a range of mobile and desktop devices, including desktop web browsers, tablets and mobile phones. The company's platform can be deployed in the cloud or on-premises, with organizations able to access the same functionality and data sources in various cases.

Gossamer Bio

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in immunology, inflammation and oncology. The company has four clinical-stage product candidates: GB001 (Prostaglandin D2 receptor 2 Antagonist), which is for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions; GB002 (Platelet-derived growth factor Receptor Kinase Inhibitor), which is for the treatment of pulmonary arterial hypertension; GB004 (Hypoxia inducible factor-1a Stabilizer), which is for the treatment of inflammatory bowel disease; and GB1275 (CD11b Modulator), which is for the treatment of oncology indications.

Oncocyte

OncoCyte is focused on developing non-invasive molecular diagnostic tests for cancer diagnosis. The company is developing DetermaVu?, a non-invasive molecular lung cancer confirmatory diagnostic that can be administered to patients as a blood test. DetermaVu? utilizes proprietary sets of gene expression markers to help confirm whether lung nodules detected via Low Dose Computed Tomography scans, x-rays or other imaging are likely to be benign or malignant. DetermaVu? is based on the company's Immune System Interrogation approach that checks the body's immune system response to a specific disease by measuring differential RNA expression in patients with the disease versus patients without the disease.

PACIFIC CITY FINANCIAL CORP

Provider
InsiderInsights.com
InsiderInsights.com

Insiderinsights' advanced insider analytics combine statistical track records with numerous behavioral metrics to rate the significance of a firm's insider trading history in real time.

Academic studies and the experience of professionals back the common sense conclusion that the Form 4 data filed daily at the SEC is a profitable data stream to mine for investment intelligence. But most investors use commodity insider feeds that are full of noise and time-consuming to analyze, or ratings services that employ last century's simplistic insider scoring methodology.

InsiderInsights compiles Daily, Weekly, and Monthly reports that list US equities with recent insider activity, along with proprietary Company Ratings clearly indicating the Significance Level of insider sentiment. Our monthly Special Screens further combine our Ratings with various fundamental and price action criteria, to highlight the best value, growth, momentum, and short ideas coming from the executive suite.

Analysts
Jonathan Moreland

Other Reports on these Companies
Other Reports from InsiderInsights.com

ResearchPool Subscriptions

Get the most out of your insights

Get in touch